What question did this study set out to answer?

The aim is to evaluate whether a gD mutant HSV-2 vaccine offers superior protection compared to a subunit vaccine.

November 12, 2015Journal of VirologyOpen Access

A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial demonstrates superior protection against HSV-2 in mice, suggesting a new vaccine strategy.

The aim is to evaluate whether a gD mutant HSV-2 vaccine offers superior protection compared to a subunit vaccine.
Vaccinated mice with a live attenuated HSV-2 vaccine impaired for neural infection.
Compared protective effects to a subunit vaccine in a controlled setting.
The gD mutant vaccine provided significantly better protection than the subunit vaccine.
Mice vaccinated with the gD mutant showed lower viral shedding compared to those receiving the subunit vaccine.

Wang et al. (2015) studied this question.

View Full Paper

Ask AI

Bookmark